Product Information
VALGANCICLOVIR 450 MG TABLET is a generic product labeled by Aurobindo Pharma Limited, priced at $1.9150 per EA under NDC 65862075360. Its NADAC has been published 545 times since Apr 27, 2016.
FDA first approved this application on Mar 31, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the VALGANCICLOVIR HYDROCHLORIDE market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
450 mg/1
Manufacturer
Aurobindo Pharma LimitedNDC
65862075360
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
VALGANCICLOVIR HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA204750FDA Approved
3/31/2016
TE Code
AB
On Market Since
3/31/2016
Pharmacological Classes
Price Statistics
The NADAC for VALGANCICLOVIR 450 MG TABLET has been published 545 times since Apr 27, 2016, and over the history we have for it it has declined 95.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.9150 per EA |
|---|---|
| All-time high | $45.0752 (May 11, 2016) |
| All-time low | $1.7596 (Nov 20, 2024) |
| 52-week high | $2.5006 |
| 52-week low | $1.8426 |
| Median price | $3.8102 |
| Average price | $7.7700 |
| Largest weekly change | -38.3% (May 17, 2017) |
| Weeks tracked | 545 |
| Tracking since | Apr 27, 2016 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the VALGANCICLOVIR HYDROCHLORIDE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Aurobindo Pharma Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
VALGANCICLOVIR HYDROCHLORIDE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of VALGANCICLOVIR 450 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for VALGANCICLOVIR 450 MG TABLET, manufactured by Aurobindo Pharma Limited, is $1.9150 per EA (NDC 65862075360), effective Sep 30, 2026.
How has the price of VALGANCICLOVIR 450 MG TABLET changed over time?
Over the history we have for it, the NADAC for VALGANCICLOVIR 450 MG TABLET has declined 95.8%. It has been tracked across 545 weekly CMS publications since Apr 27, 2016.
What are the highest and lowest recorded NADAC prices for VALGANCICLOVIR 450 MG TABLET?
Since Apr 27, 2016, the NADAC for VALGANCICLOVIR 450 MG TABLET has ranged from a low of $1.7596 (Nov 20, 2024) to a high of $45.0752 (May 11, 2016), with a median of $3.8102 per EA.
Are there cheaper alternatives to VALGANCICLOVIR 450 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of VALGANCICLOVIR 450 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures VALGANCICLOVIR 450 MG TABLET?
VALGANCICLOVIR 450 MG TABLET (NDC 65862075360) is labeled by Aurobindo Pharma Limited, and CMS classifies it as a generic product.